A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies

Trial Profile

A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs IMG 7289 (Primary) ; Tretinoin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Imago BioSciences
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 21 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Feb 2018.
    • 19 Jul 2017 According to an Imago BioSciences media release, the phase I multiple ascending dose portion of the study has been completed (n = 19), and first patients have been dosed in the phase IIa portion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top